FILTER

FILTERED INTERVIEW RESULTS

Ben Bradford

HEAD OF EXTERNAL AFFAIRS, MASSBIO
"It is the Massachusetts story — early-stage companies developing great science, commercial giants with a local presence, and financial partnerships that turn ideas into treatments."

Tim Scott

PRESIDENT AND CEO, BIOCOM CALIFORNIA
"We have recognized the synergies between the life science and tech industries, and have worked to foster relationships that can accelerate therapeutic, medical device and diagnostic development."

Eddie Pauline

PRESIDENT AND CEO, OHIO LIFE SCIENCES
"Ohio is increasingly competitive in attracting larger, well-known life science brands, plus our institutions continue to spin out new biotech companies; people across the country are starting to notice."

Takahiro Ueda

CEO, CMIC CMO USA
"Continuous manufacturing is key to our US strategy, differentiating us in the market."

Louis P. Kassa III

CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Better alignment between institutions and industry can drive innovation, scientific progress, and economic growth in the coming years."

Steve Favaloro

CHAIRMAN AND CEO, GENEZEN
"Investors are finding it difficult to balance early-phase success with the commercialization hurdles ahead."

Dirk Lange

CEO, PYRAMID LABS
"Alignment on business strategy, culture and operational philosophy is now a critical factor in vendor selection."

Jeff Parshley

CORPORATE CONSULTANT, SRK
"We increasingly acknowledge the need to factor extreme climatic events into our designs and operational plans."

Mitchell Krebs

CEO, COEUR MINING
"After years of heavy investment, we have fundamentally transformed the company and everything is aligning in a way that is incredibly exciting."

Stephen Twyerould

PRESIDENT AND CEO, GUNNISON COPPER CORP
"Arizona has seen a surge of investor interest, with new government funding sources now available and fast-tracking permitting options helping many copper development projects."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS